文献速递消化系统肿瘤

转移性结直肠癌患者循环肿瘤DNA的RAS突变分析:AGEO RASANC前瞻性多中心研究

RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study.
PubMed 文献 · Ann Oncol · 2018-01-01

该前瞻性多中心研究比较了血浆与组织RAS分析在转移性结直肠癌化疗初治患者中的一致性,共纳入425例患者。在412例有配对样本的患者中,κ系数为0.71,准确率为85.2%;在329例可检测到ctDNA的患者中,κ系数为0.89,准确率为94.8%。无肝转移是ctDNA结果不确定的主要临床因素。

要点

  • 血浆与组织RAS状态在总体人群中一致性中等(κ=0.71),在可检测ctDNA者中一致性极好(κ=0.89)。
  • 无肝转移是ctDNA结果不确定的主要因素(OR=0.11)。
  • 肝转移患者中,NGS联合甲基化标志物准确率达97%。

核心结论

  • 血浆与肿瘤组织RAS状态在转移性结直肠癌患者中具有高度一致性,尤其在肝转移患者中,支持血浆检测用于常规RAS突变分析。

研究设计与样本

  • 前瞻性多中心研究,纳入425例化疗初治的转移性结直肠癌患者,前瞻性收集血浆样本,中心实验室采用NGS(colon lung cancer V2 Ampliseq panel)和甲基化数字PCR(WIF1和NPY基因)分析,同时按常规实践本地检测肿瘤RAS状态。

主要发现

  • 在412例有配对血浆和组织样本的患者中,κ系数为0.71(95%CI 0.64-0.77),准确率为85.2%(95%CI 81.4%-88.5%)。
  • 在329例可检测到ctDNA(至少一个突变或一个甲基化生物标志物)的患者中,κ系数为0.89(95%CI 0.84-0.94),准确率为94.8%(95%CI 91.9%-97.0%)。
  • 无肝转移是ctDNA结果不确定的主要临床因素(OR=0.11,95%CI 0.06-0.21)。
  • 在肝转移患者中,仅NGS的准确率为93.5%,NGS联合甲基化生物标志物的准确率为97%。

关键数值与推荐

  • 为达到最小κ系数0.7(反映可接受的一致性,精度±0.07),并估计5%数据不可利用,所需样本量为425例。

临床怎么用

  • 对于转移性结直肠癌患者,尤其是肝转移患者,血浆ctDNA检测可用于RAS突变分析,以缩短检测时间并指导抗EGFR抗体治疗。

局限性

  • 无肝转移患者中ctDNA结果不确定性较高,可能限制血浆检测在这类患者中的应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: RAS mutations are currently sought for in tumor samples, which takes a median of almost 3 weeks in western European countries. This creates problems in clinical situations that require urgent treatment and for inclusion in therapeutic trials that need RAS status for randomization. Analysis of circulating tumor DNA might help to shorten the time required to determine RAS mutational status before anti-epidermal growth factor receptor antibody therapy for metastatic colorectal cancer. Here we compared plasma with tissue RAS analysis in a large prospective multicenter cohort. PATIENTS AND METHODS: Plasma samples were collected prospectively from chemotherapy-naive patients and analyzed centrally by next-generation sequencing (NGS) with the colon lung cancer V2 Ampliseq panel and by methylation digital PCR (WIF1 and NPY genes). Tumoral RAS status was determined locally, in parallel, according to routine practice. For a minimal κ coefficient of 0.7, reflecting acceptable concordance (precision ± 0.07), with an estimated 5% of non-exploitable data, 425 subjects were necessary. RESULTS: From July 2015 to December 2016, 425 patients were enrolled. For the 412 patients with available paired plasma and tumor samples, the κ coefficient was 0.71 [95% confidence interval (CI), 0.64-0.77] and accuracy was 85.2% (95% CI, 81.4% to 88.5%). In the 329 patients with detectable ctDNA (at least one mutation or one methylated biomarker), the κ coefficient was 0.89 (95% CI, 0.84-0.94) and accuracy was 94.8% (95% CI, 91.9% to 97.0%). The absence of liver metastases was the main clinical factor associated with inconclusive circulating tumor DNA results [odds ratio = 0.11 (95% CI, 0.06-0.21)]. In patients with liver metastases, accuracy was 93.5% with NGS alone and 97% with NGS plus the methylated biomarkers. CONCLUSION: This prospective trial demonstrates excellent concordance between RAS status in plasma and tumor tissue from patients with colorectal cancer and liver metastases, thus validating plasma testing for routine RAS mutation analysis in these patients. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov, NCT02502656.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Bachet JB, Bouché O, Taieb J, et al. RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study. Ann Oncol. 2018. PMID: 29438522. doi:10.1093/annonc/mdy061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。